Unknown

Dataset Information

0

Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.


ABSTRACT: Heterogeneity in the clinical presentation of SARS-CoV-2 infection and COVID-19 progression underscores the urgent need to identify individual-level susceptibility factors that affect infection vulnerability and disease severity. Tobacco product use is a potential susceptibility factor. In this Personal View, we provide an overview of the findings of peer-reviewed, published studies relating tobacco product use to SARS-CoV-2 infection and COVID-19 outcomes, with most studies focusing on cigarette smoking in adults. Findings pertaining to the effects of tobacco product use on the incidence of SARS-CoV-2 infection are inconsistent. However, evidence supports a role for cigarette smoking in increasing the risk of poor COVID-19 outcomes, including hospital admission, progression in disease severity, and COVID-19-related mortality. We discuss the potential effects of tobacco use behaviour on SARS-CoV-2 transmission and infection, and highlight the pathophysiological changes associated with cigarette smoking that could promote SARS-CoV-2 infection and increased disease severity. We consider the biological mechanisms by which nicotine and other tobacco product constituents might affect immune and inflammatory responses to SARS-CoV-2 infection. Finally, we identify current knowledge gaps and suggest priorities for research to address acute and post-acute health outcomes of COVID-19 during and after the pandemic.

SUBMITTER: Benowitz NL 

PROVIDER: S-EPMC9381032 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.

Benowitz Neal L NL   Goniewicz Maciej L ML   Halpern-Felsher Bonnie B   Krishnan-Sarin Suchitra S   Ling Pamela M PM   O'Connor Richard J RJ   Pentz Mary Ann MA   Robertson Rose Marie RM   Bhatnagar Aruni A  

The Lancet. Respiratory medicine 20220816 9


Heterogeneity in the clinical presentation of SARS-CoV-2 infection and COVID-19 progression underscores the urgent need to identify individual-level susceptibility factors that affect infection vulnerability and disease severity. Tobacco product use is a potential susceptibility factor. In this Personal View, we provide an overview of the findings of peer-reviewed, published studies relating tobacco product use to SARS-CoV-2 infection and COVID-19 outcomes, with most studies focusing on cigarett  ...[more]

Similar Datasets

| S-EPMC5165261 | biostudies-other
| S-EPMC10292824 | biostudies-literature
| S-EPMC6149364 | biostudies-literature
| S-EPMC10286680 | biostudies-literature
| S-EPMC5758462 | biostudies-literature
| S-EPMC7315836 | biostudies-literature
| S-EPMC7953960 | biostudies-literature
| S-EPMC6532893 | biostudies-literature
| S-EPMC7799234 | biostudies-literature
| S-EPMC9278178 | biostudies-literature